| Hans-Günter Meyer-Thompson | Opioide
USA. FDA Briefing Document: Postmarketing safety issues related to reformulated Opana ER® (Oxymorphone retard, Anmerkung Forum Substitutionspraxis)
Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and the Anesthetic and
Analgesic Drug Products Advisory Committee (AADPAC)
Meeting March 13 -14, 2017